Table 3. Risk factors for erroneous and unintentional deviations from the guidelines in inpatients using dual antiplatelet therapy .
| Risk factor | n/N (%) in erroneous deviation from guidelines | Univariate logistic regression | |||
|---|---|---|---|---|---|
| OR | 95% CI | p-value | |||
| Gender | |||||
| Male | 9/244 | 3.7 % | Ref. | ||
| Female | 2/167 | 1.2 % | 0.32 | 0.07-1.48 | 0.14 |
| Age | 1.06 | 1.00-1.12 | 0.06 | ||
| DAPT before admission | |||||
| No | 3/353 | 0.8 % | Ref. | ||
| Yes | 8/58 | 13.8 % | 18.7 | 4.79-72.7 | <0.0001 |
| DAPT | |||||
| ASA + clopidogrel | 10/258 | 3.9 % | Ref. | ||
| ASA + prasugrel | 0/2 | N/A | 0.16 a | 0.02-1.29 | 0.09 |
| ASA + ticagrelor | 1 / 151 | 0.7 % | |||
| Indication | |||||
| Cardiovascular | 6/213 | 2.8 % | Ref. | ||
| Neurologic | 4/193 | 2.1 % | 0.73 | 0.20-2.63 | 0.63 |
| Surgical | 0/3 | N/A | 8.63 a | 0.83-89.3 | 0.07 |
| Multiple | 1/2 | 50 % | |||
a
the DAPT therapies ASA + prasugrel and ASA + ticagrelor and the indications surgical and multiple were analyzed as one group in the regression analyses due to low numbers.
DAPT: dual antiplatelet therapy; ASA: acetylsalicylic acid; N/A: not applicable; OR: odds ratio; CI: confidence interval